NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyGenX molecular thyroid test will now be covered by Cigna.

The test uses next-generation sequencing to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, and is designed to assess fine needle aspiration samples from indeterminate thyroid nodules.